Fonar (NASDAQ:FONR) Stock, Quote.Headers.trade-ideas

Fonar

Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADVM

AEMD

AESE

AKUS

APOG

ASFI

AXSM

BBCP

BBGI

BCLI

BrightSphere Investment Group plc Ordinary Shares

BSIG

BSVN

BYFC

CAMP

CARV

CIDM

CLGX

CLSK

CTIB

CTXR

CVGI

CWBR

DBVT

EKSO

FLMN

FONR

GLBS

GRAF

GWGH

IBIO

IBKC

IDEX

IDXG

IPDN

KTOV

LCUT

MDCA

MINI

MLSS

MMLP

MMYT

PASG

PHCF

PHUN

PRGX

RCON

REFR

SHIP

SHLL

SINT

SOLY

SWTX

TBIO

TELA

UTSI

VBIV

VXRT

WINS

WKHS

Gainers


	Concrete Pumping Holdings, Inc. (NASDAQ: BBCP) shares jumped 50.1% to close at $5.48 on Friday.


81 Biggest Movers From Friday

Intraday Update

AACG

AAOI

ABCB

ABMD

ACCO

ACEL

ACGL

ACHC

ACHV

ACIU

ACRE

ACRX

ACST

ACTG

ADES

ADMP

ADMS

ADNT

ADOM

ADPT

ADTN

AEHR

AEIS

AERI

AEZS

AFGC

AFIN

AFMD

AGFS

AGLE

AGRO

AGYS

AIMC

AIMT

AINV

AIRT

AKCA

AKTS

AKTX

ALBO

ALDX

ALEX

ALGN

ALGT

Stocks That Hit 52-Week Lows On Monday

AAWW

AKRX

AMAL

AMCR

AMPY

AMSC

ANAT

ANCN

ANIX

APAM

APEI

ARAY

ARCH

ARCO

ARLO

AROC

ASPS

ATEN

Adtalem Global Education Inc. Common Stock

ATGE

ATOS

ATSG

AUTL

AVAL

AVCO

AWSM

AXGN

AXTA

BANC

BANX

BATRA

BATRK

BBDC

BCSF

BEDU

BELFA

BERY

BHAT

BJRI

BKSC

BLBD

BLMN

BORR

BRFS

BSET

BSGM

Stocks That Hit 52-Week Lows On Wednesday

Fonar Corp

<ul>
<li>Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier.</li>
<li>Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.</li>
<li>Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.</li>
<li>Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.</li>
<li>Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.</li>
<li>Diluted Net Income per Common Share decreased 22% to $0.46 for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.</li>
<li>Working Capital increased by 2% to $124.7 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.</li>
<li>Book Value Per Share was $25.32 for the quarter ended September 30, 2024 as compared to $23.88 at September 30, 2023.</li>
<li>One HMCA-managed MRI scanner was added in the first quarter of fiscal 2024, bringing the total number of managed scanners to 43.</li>
</ul>


Earnings

Health Care

General

Fonar Q1 2025 EPS $0.46 Down From $0.59 YoY, Sales $24.96M Down From $25.84M YoY

<p>Fonar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) reported quarterly earnings of $0.55 per share. This is a 71.88 percent increase over earnings of $0.32 per share from the same period last year.  The company reported $25.42 million in sales this quarter. This is a 3.46 percent increase over sales of $24.57 million the same period last year.</p>


Fonar Q3 EPS $0.55 Up From $0.32 YoY, Sales $25.42M Up From $24.57M YoY

FONAR FY22 EPS $0.50, Sales $97.59M

<h3>What are Value Stocks?</h3>
<p>A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. </p>
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li><strong>Werewolf Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) - P/E: 1.02</li>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.48</li>
<li><strong>ITeos Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) - P/E: 2.59</li>
<li><strong>Assertio Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) - P/E: 4.71</li>
<li><strong>QuidelOrtho</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) - P/E: 3.69</li>
</ol>
<p>This quarter, Werewolf Therapeutics experienced an increase in earnings per share, which was $-0.56 in Q1 and is now $-0.53. Most recently, Fonar reported earnings per share at $0.32, whereas in Q2 earnings per share sat at $0.57. ITeos Therapeutics saw a decrease in earnings per share from 1.82 in Q1 to $0.15 now. Assertio Holdings saw a decrease in earnings per share from 0.38 in Q1 to $0.28 now. QuidelOrtho saw a decrease in earnings per share from 11.66 in Q1 to $2.34 now. </p>
<p>These 5 value stocks were selected by <strong>Benzinga Insights</strong> based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.</p>


ASRT

HOWL

ITOS

QDEL

Overview Of Value Stocks In The Healthcare Sector

<h3>What is a Value Stock?</h3>
<p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. </p>
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li><strong>Achilles Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) - P/E: 0.44</li>
<li><strong>Sensus Healthcare</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) - P/E: 8.73</li>
<li><strong>Global Cord Blood</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CO#NYSE">CO</a>) - P/E: 4.01</li>
<li><strong>BioNTech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) - P/E: 3.27</li>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.48</li>
</ol>
<p>Achilles Therapeutics has been featured as a value stock. Achilles Therapeutics's Q1 EPS sits at $-0.45, which has not changed since last quarter (Q4). Sensus Healthcare saw a decrease in earnings per share from 0.32 in Q4 to $0.2 now. This quarter, Global Cord Blood experienced a decrease in earnings per share, which was $0.17 in Q3 and is now $0.14. BioNTech has reported Q1 earnings per share at $15.97, which has increased by 14.64% compared to Q4, which was 13.93. Most recently, Fonar reported earnings per share at $0.32, whereas in Q2 earnings per share sat at $0.57. </p>
<p><strong>The Significance:</strong> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>


ACHL

BNTX

SRTS

5 Value Stocks In The Healthcare Sector

<h3>What is a Value Stock?</h3>
<p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. </p>
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li><strong>eFFECTOR Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) - P/E: 1.81</li>
<li><strong>Quest Diagnostics</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) - P/E: 9.05</li>
<li><strong>Ironwood Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) - P/E: 3.68</li>
<li><strong>Global Cord Blood</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CO#NYSE">CO</a>) - P/E: 4.13</li>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.51</li>
</ol>
<p>eFFECTOR Therapeutics saw a decrease in earnings per share from 0.44 in Q4 to $0.07 now. Quest Diagnostics saw a decrease in earnings per share from 3.33 in Q4 to $3.22 now. Most recently, the company reported a dividend yield of 1.95%, which has increased by 0.01% from last quarter's yield of 1.94%.</p>
<p>Ironwood Pharmaceuticals has reported Q1 earnings per share at $0.21, which has decreased by 22.22% compared to Q4, which was 0.27. Global Cord Blood's earnings per share for Q4 sits at $0.14, whereas in Q3, they were at 0.17. Fonar's earnings per share for Q3 sits at $0.32, whereas in Q2, they were at 0.57. </p>
<p>These 5 value stocks were selected by <strong>Benzinga Insights</strong> based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.</p>


EFTR

IRWD

<h3>The Meaning Behind Value Stocks</h3>
<p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. </p>
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li><strong>Co-Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) - P/E: 4.56</li>
<li><strong>QuidelOrtho</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) - P/E: 4.5</li>
<li><strong>Iterum Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) - P/E: 1.04</li>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.69</li>
<li><strong>BioNTech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) - P/E: 3.38</li>
</ol>
<p>This quarter, Co-Diagnostics experienced an increase in earnings per share, which was $0.25 in Q4 and is now $0.34. Most recently, QuidelOrtho reported earnings per share at $11.66, whereas in Q4 earnings per share sat at $7.29. Most recently, Iterum Therapeutics reported earnings per share at $-0.03, whereas in Q4 earnings per share sat at $-0.02. Fonar's earnings per share for Q3 sits at $0.32, whereas in Q2, they were at 0.57. BioNTech saw an increase in earnings per share from 13.93 in Q4 to $15.97 now. </p>
<p>These 5 value stocks were selected by <strong>Benzinga Insights</strong> based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.</p>


CODX

ITRM

5 Value Stocks To Watch In The Healthcare Sector

<h3>What Defines a Value Stock?</h3>
<p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. </p>
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li><strong>Co-Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) - P/E: 3.81</li>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 8.95</li>
<li><strong>Select Medical Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) - P/E: 9.6</li>
<li><strong>Achilles Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) - P/E: 0.43</li>
<li><strong>Sensus Healthcare</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) - P/E: 6.76</li>
</ol>
<p>Co-Diagnostics's earnings per share for Q1 sits at $0.34, whereas in Q4, they were at 0.25. Fonar has reported Q3 earnings per share at $0.32, which has decreased by 43.86% compared to Q2, which was 0.57. Select Medical Holdings looks to be undervalued. It possesses an EPS of $0.37, which has not changed since last quarter (Q4). Most recently, the company reported a dividend yield of 2.16%, which has increased by 0.09% from last quarter's yield of 2.07%.</p>
<p>Achilles Therapeutics has been featured as a value stock. Achilles Therapeutics's Q1 EPS sits at $-0.45, which has not changed since last quarter (Q4). Sensus Healthcare saw a decrease in earnings per share from 0.32 in Q4 to $0.2 now. </p>
<p><strong>The Significance:</strong> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>


<h3>What are Value Stocks?</h3>
<p>A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. </p>
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.96</li>
<li><strong>Regeneron Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) - P/E: 8.87</li>
<li><strong>Surface Oncology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURF#NASDAQ">SURF</a>) - P/E: 6.2</li>
<li><strong>uniQure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) - P/E: 2.45</li>
<li><strong>Tenet Healthcare</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) - P/E: 9.69</li>
</ol>
<p>Fonar has reported Q2 earnings per share at $0.57, which has increased by 3.64% compared to Q1, which was 0.55. Most recently, Regeneron Pharmaceuticals reported earnings per share at $23.72, whereas in Q3 earnings per share sat at $15.37. Surface Oncology has been featured as a value stock. Surface Oncology's Q3 EPS sits at $-0.44, which has not changed since last quarter (Q2). uniQure's earnings per share for Q3 sits at $-0.79, whereas in Q2, they were at 8.51. Most recently, Tenet Healthcare reported earnings per share at $2.7, whereas in Q3 earnings per share sat at $1.99. </p>
<p>These 5 value stocks were selected by <strong>Benzinga Insights</strong> based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.</p>


QURE

REGN

SURF

<h3>What Defines a Value Stock?</h3>
<p>A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. </p>
<h2>The following stocks are considered to be notable value stocks in the healthcare sector:</h2>
<ol>
<li><strong>Fonar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) - P/E: 9.13</li>
<li><strong>PainReform</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) - P/E: 3.5</li>
<li><strong>Cigna</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) - P/E: 9.72</li>
<li><strong>Collegium Pharmaceutical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) - P/E: 7.13</li>
<li><strong>Select Medical Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) - P/E: 9.22</li>
</ol>
<p>Most recently, Fonar reported earnings per share at 0.55, whereas in Q4 earnings per share sat at 0.1. PainReform has reported Q3 earnings per share at -0.18, which has increased by 30.77% compared to Q2, which was -0.26. Cigna saw an increase in earnings per share from 5.24 in Q2 to 5.73 now. The company's most recent dividend yield sits at 1.85%, which has increased by 0.1% from 1.75% last quarter. </p>
<p>This quarter, Collegium Pharmaceutical experienced a decrease in earnings per share, which was 0.27 in Q2 and is now 0.22. Select Medical Holdings saw a decrease in earnings per share from 1.22 in Q2 to 0.57 now. The company's most recent dividend yield sits at 1.48%, which has increased by 0.22% from 1.26% last quarter. </p>
<p><strong>The Significance:</strong> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>


COLL

PRFX

<p>Fonar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) reported quarterly earnings of $0.55 per share. This is a 52.78 percent increase over earnings of $0.36 per share from the same period last year.  The company reported $23.70 million in sales this quarter. This is a 12.97 percent increase over sales of $20.98 million the same period last year.</p>


Fonar Q1 EPS $0.55 Up From $0.36 YoY, Sales $23.70M Up From $20.98M YoY

Comments

Fonar

Fonar (FONR) Forecast

Fonar (NASDAQ:FONR) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga